Search

Displaying results 1571 - 1580 of 5392 in total
  1. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

    Synonyms: D-Cephaloglycine, D-(-)-Cephaloglycin
  2. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durval...

  3. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent ver...

    Categories: Dopamine D2 Receptor Antagonists
  4. Drug

    Plinabulin

    go.drugbank.com/drugs/DB05992
    Investigational

  5. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single

  6. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    Due to its water-binding property, cetyl alcohol is commonly used as an emollient that prevents drying and chapping of the skin [A32209].

  7. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknow...

    Categories: Dopamine D2 Receptor Antagonists
  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  9. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic

  10. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.